We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information and guidance on a range of medical devices for users and patients.
Advice for medical professionals to follow when assessing drivers with diabetes mellitus.
Advice for healthcare professionals on how to use blood glucose meters safely and effectively.
Experiences from a self-monitoring of blood glucose (SMBG) program in western Kenya
Data analysis was performed using the chi-square test and multivariate logistic regression
Scientific opinion from the UK Nutrition and Health Claims Committee (UKNHCC) for the substantiation of an Article 14(1)(a) health claim: Morus alba leaf extract and blood glucose levels.
How to use an interrupted time series to evaluate your digital health product.
Globally, diabetes contributes to 15% of TB burden and is a risk factor for unfavourable TB treatment outcomes
Device-specific guidance for manufacturers on reporting adverse incidents under the vigilance system
Guidance for healthcare professionals covers the use, management and safety of in vitro diagnostic (IVD) devices, including blood glucose meters.
Letter from Dr Rowan Hillson.
This study reported high prevalence, especially of undiagnosed cases amongst adults, most have uncontrolled blood sugar levels
How to use a cost effectiveness analysis to evaluate your digital health product.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (21 May 2024) launched a four-week consultation which will support improved safety for certain high risk in vitro diagnostic (IVD) devices.
This trial was conducted during routine outpatient department hours in a primary health care setting in Puducherry, India
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).